OSI Pharmaceuticals OSIP
-
Do Mergers Mean Billions for Biotech?
Michael Becker submits: In March 2009, we asked the question “ Where Might Genentech Investors Redeploy $47 Billion? ” in response to the news that Roche Holding AG ( RHHBY.PK ) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in ...
-
Sanofi Buys More Time with Extended Genzyme Offer
… deals in the biotech space, including Roche's RHHBY acquisition of Genentech and Astellas' acquisition of OSI Pharmaceuticals . An alternative to a higher bid would be the incorporation of a contingent value right into the deal, to account …
-
Sanofi's Hostile Offer for Genzyme Could Help Focus Negotiations
… deals in the biotech space, including Roche's RHHBY acquisition of Genentech and Astellas' acquisition of OSI Pharmaceuticals . We continue to see a deal closing near our $78 fair value estimate. As we've discussed previously, there …
-
HGHCX Hartford Global Health C Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… Although some of the fund's stocks have hit a rough patch, others have been big winners. Biotech company OSI Pharmaceuticals was recently acquired, much to the benefit of the fund, and Incyte INCY has also done well. More importantly …
-
Our Outlook for Health-Care Stocks
… firms manifested itself in the heavy volume of mergers and acquisitions in the quarter. Astellas Pharma acquired OSI Pharmaceuticals for $4 billion in the quarter giving the Japanese pharma firm a promising cancer treatment and a robust pipeline …
-
Japan's Astellas buys OSI for $4B
TOKYO (AP) -- Astellas Pharma Inc., Japan's No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide. Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month. http://finance.yahoo.com/news That's about 50 times TTM earnings, or a 2% return for the Japanese company. OSI must have a good pipeline to be worth that much to them. Astellas is the number 2 drug company in Japan, however, I assume they'll keep most of the OSI American employees in place, after all, in the R&D business, it's personel that you're after. Can't see where regulators in either country or the EU will have a problem with this.
-
Astellas Raises Offer Price for OSI
After several months of haggling , OSI Pharmaceuticals OSIP and Japanese drugmaker Astellas Pharma have finally come to an agreement regarding a fair price for control of OSI . Astellas …
-
New Credit Rating: OSI Pharmaceuticals
… issuer credit rating for OSI Pharmaceuticals OSIP at BBB + , reflecting our ..... prospects look solid as well . OSI Pharmaceuticals hit a home run with the ..... attempting to purchase OSI Pharmaceuticals . This hostile bid attempt …
-
Raising OSI's Fair Value Estimate
We are raising our fair value estimate for OSI Pharmaceuticals OSIP after dialing up our sales estimates for Tarceva in the wake of the drug's recent label expansion and factoring a takeout scenario …
-
New Morningstar Analyst Report - OSI Pharmaceuticals , Inc.
… pursue smart purchases . OSI Pharmaceuticals discovers and develops biopharmaceutical ..... Pharmaceuticalshttp : / / osip . client . shareholder ..... Pharmaceuticalshttp : / / www . osip . com / products _ pipelinePipelineWith ..... for obesity and diabetes . OSI Pharmaceuticals hit a home run with the discovery …